Sanifit
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ctra Valldemossa Km7.4 Building Fl 2, Pa...Phone Number
+34 971439925Website
www.sanifit.comRevenue
$9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Sanifit
Sanifit is a biopharmaceutical company focused on calcification disorders. The company launched in 2007 as a spin-off from the University of the Balearic Islands.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sanifit your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Sanifit, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Sanifit has new funding data
Earning: See what the market has to say on Sanifit recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Sanifit had a recent Job posting/layoffs
Check out if Sanifit is spiking on competitors!
Product Launch: Get notified when Sanifit launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sanifit has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sanifit
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Sanifit is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sanifit is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sanifit.
Sanifit financials insights
Gather financial insights about Sanifit, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series C
$29.5M
Series B
$41M
2019
Series D
$80.9M
Sanifit Tech Stack
A closer look at the technologies used by Sanifit
See more technologies
Most Recent Scoops
Left Company
Executive Move
Sanifit has announced that Adam Levy, Chief Financial Officer, has left the organization to join Mineralys Therapeutics as Chief Financial & Business Officer.
Mergers & Acquisitions (M&A)
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Funding
Sanifit News & Media
Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of EUR205m
Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of EUR205m Submitted 23/11/2021 - 10:05am Caixa Capital Risc, the venture capital subsidiary of CriteriaCaixa, has sold its portfolio company Sanifit Therapeutics to Vifor Pharma, a global pharmaceutical company that aims to become an industry leader in iron deficiency, nephrology and cardio-renal therapies. Under the terms of the agreement, Vifor Pharma will acquire 100 per cent of the outstanding sharesSanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of ...
The poster child of the Spanish biotech scene has secured its exit. Having twice smashed the Spanish biotech financing record in recent years, Sanifit has now accepted a 205 million euro ($231 million) buyout bid from Vifor Pharma.Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
ST. GALLEN, Switzerland & PALMA, Spain & ZURICH--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disSanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral ...
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sanifit
Sign Up For FreeTo access detailed company insights
Sanifit is a biopharmaceutical company focused on calcification disorders. The company launched in 2007 as a spin-off from the University of the Balearic Islands.... Read More
